SDPA News: Emrosi Shows Efficacy Independent of Body Weight Differences in Rosacea
Differences in body weight do not affect the efficacy of Journey’s Emrosi (minocycline hydrochloride extended-release capsules) in rosacea, according to two Phase 3 trials slated to be presented at the Society of Dermatology Physician Associates (SDPA) 2025 Summer Dermatology Conference in Washington, DC. “This analysis demonstrated that Emrosi is body weight independent, which means it […]